The IP Solution
After working with the company to evaluate their internal competencies and identify gaps in their commercialization strategy, IP engaged in an assessment of the oncology clinical pathways climate in relation to this new therapy.
Following this in-depth market analysis, we developed a strategy to support their coding and reimbursement needs—including an extremely quick turnaround to identify the viability of an NTAP designation, and later, the development and submission of an application to CMS.
Additionally, in collaboration with the Market Access and Medical Affairs teams, IP supported the development and submission of applications for the product’s inclusion in the five major oncology clinical compendia and several major pathways organizations. We also provided support for outreach and engagement with the major pathways vendors, EMR vendors, and payers.